



**UNITED STATES  
NUCLEAR REGULATORY COMMISSION**  
REGION I  
2100 RENAISSANCE BOULEVARD, SUITE 100  
KING OF PRUSSIA, PA 19406-2713

March 30, 2015

Docket No. 03033449  
Control No. 585813

License No. 44-30124-01MD

Richard L. Van Sant, Pharm.D.  
Director of Regulatory Affairs  
PharmaLogic Ltd.  
1191 S. Brownell Road, Suite 40  
Williston, VT 05495

SUBJECT: PHARMALOGIC LTD., LICENSE AMENDMENT, CONTROL NO. 585813

Dear Dr. Van Sant:

By letter dated January 20, 2015, PharmaLogic Ltd. submitted to the U.S. Nuclear Regulatory Commission (NRC) a request for consent to indirect license transfer of NRC Materials License No. 44-30124-01MD. Based on the information you provided, we understand that as a result of a proposed merger between PL Holding Merger Sub, Inc. into PharmaLogic Holdings Corp., PharmaLogic Holdings Corp. will be the surviving corporation. PharmaLogic Holdings Corp. will continue to operate its business and own its subsidiaries, including PharmaLogic, Ltd. We further understand that this transfer will not result in any change to the licensed name, licensed materials, persons using the licensed material, location of use of licensed material, or persons responsible for the licensee's radiation safety program.

Based on the above understandings and as more fully detailed in the enclosed NRC staff's Safety Evaluation Report which documents the NRC staff's review of the request, we have no objection to the proposed transfer. We understand that the merger will take place on March 31, 2015. Enclosed with this letter is the amended license.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Current NRC regulations and guidance are included on the NRC's website at [www.nrc.gov](http://www.nrc.gov); select **Nuclear Materials; Med, Ind, & Academic Uses**; then **Licensee Toolkits**, see our **toolkit index page**. You may also obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-866-512-1800. The GPO is open from 8:00 a.m. to 5:30 p.m. EST, Monday through Friday (except Federal holidays).

In accordance with 10 CFR 2.390 of the NRC's "Agency's Rules of Practice and Procedure," a copy of this letter will be available electronically for public inspection in the NRC Public Document Room or from the Publicly Available Records component of NRC's Agencywide Documents Access and Management System (ADAMS). ADAMS is accessible from the NRC website at <http://www.nrc.gov/reading-rm/adams.html>.

Thank you for your cooperation.

Sincerely,

***Original signed by Tara L. Weidner***

Tara L. Weidner  
Senior Health Physicist  
Medical Branch  
Division of Nuclear Materials Safety

Enclosures:

1. Amendment No. 29
2. Safety Evaluation Report

cc:

Richard Sucese, R.Ph., Radiation Safety Officer

DOCUMENT NAME: G:\WordDocs\Current\Lic Cvr Letter\L44-30124-01.585813.doc

**SUNSI Review Complete: JNguyen**

After declaring this document "An Official Agency Record" it will be released to the Public.

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	N	DNMS/RI	N	DNMS/RI		
NAME	JNguyen/JN		TLWeidner/TW				
DATE	3-30-15		3/30/15				

OFFICIAL RECORD COPY